Pfizer Inc.
Pfizer Research Technology Center (RTC)
620 Memorial Drive
Cambridge
Massachusetts
02139
United States
Tel: 617-551-3000
Fax: 617-551-3111
Website: http://www.pfizer.com/
About Pfizer Inc.
The Pfizer Research Technology Center (RTC) in Cambridge, MA houses cutting edge research groups focused on RNAi therapeutics, Systems Biology and Biological Profiling, Regenerative Medicine and Computational Sciences.
Headquartered at the RTC, and comprising research groups in Cambridge and Düsseldorf, the goal of Pfizer RNAi Therapeutics is clear - delivering RNAi therapies to meet our patient needs and in doing so helping Pfizer become a top tier biotherapeutics company.
Pfizer Regenerative Medicine is collaborating with local experts to develop Stem Cell Therapies to treat diseases.
The Systems Biology, Biological Profiling and Computational Sciences groups are using their niche skills and expertise to focus on increasing the effectiveness of the research process through better target selection, reduced attrition and the ability to manipulate and manage data to support the research process.
Without the constraints of a therapeutic area portfolio, RTC colleagues are free to apply cutting-edge techniques and technologies with broad utility across different therapeutic areas.
The RTC is located in one of the richest scientific environments in the world, surrounded by more than 300 biotechnology companies and thousands of scientific innovators in world-leading research hospitals and academic institutions. A key element in the success of the RTC is the growing and dynamic portfolio of partnerships with these innovators, focused on addressing the strategic needs of the site and of Pfizer's research division.
The RTC aims to balance the strength of Pfizer R&D with the nimble feel of a small biotech, and creates an exciting and team-based scientific environment for 150 colleagues, with a wide range of scientific skills and experience. The working environment emphasizes collaboration and cooperation with most scientific questions solved through the work of a cross-disciplinary team. The unique working environment - truly a small biotech with the backing of the largest research budget in the industry - supports the unique science of the site.
For more information, please visit www.pfizercambridge.com
112 articles about Pfizer Inc.
-
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
1/12/2022
Pfizer Inc. (NYSE:PFE) today announced positive top-line results from a Phase 3 study (B74710126) describing the safety and immunogenicity of PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in the United States 65 years of age or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.
-
Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies
1/11/2022
Jan. 11, 2022 13:00 UTC – Strategic collaboration with Pfizer leverages Dren Bio’s proprietary platform to develop bispecific antibodies that connect tumor cells with myeloid cells resulting in immune stimulation, targeted phagocytosis and the cross-presentation of tumor neoantigens to potentially promote durable clinical responses – – Dren Bio received $25 million upfront payment as part of overall deal for selected oncology targets that includes over $1 billion in potenti
-
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
1/3/2022
First emergency use authorization in the United States for a COVID-19 vaccine booster in adolescents 12 through 15 years of age.
-
Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts
12/28/2021
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 8, 2022.
-
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply
12/20/2021
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY ® to Help Meet Continued Need for Vaccine Supply.
-
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
12/14/2021
Pfizer Inc. today announced final results from an analysis of all 2,246 adults enrolled in its Phase 2/3 EPIC-HR trial of its novel COVID-19 oral antiviral candidate PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets).
-
Pfizer to Acquire Arena Pharmaceuticals
12/13/2021
Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.
-
Pfizer and BioNTech Provide Update on Omicron Variant
12/8/2021
Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers.
-
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate
12/7/2021
Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live webcast of a presentation and conference call with investment analysts at 8:30 a.m. EST on Friday, December 17, 2021.
-
NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Combination Therapies for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
11/30/2021
NiKang Therapeutics Inc. today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE: PFE) to evaluate NKT2152.
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
11/24/2021
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Bob Smith, Vice President, Pfizer Rare Disease, at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 5:10 p.m. Eastern Standard Time.
-
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
11/19/2021
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of ARV-471 will be presented in a spotlight poster-discussion session at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 7-10, 2021.
-
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
11/18/2021
If approved or authorized, PAXLOVID™ (PF-07321332; ritonavir) would be the first oral antiviral of its kind, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2.
-
Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio
11/17/2021
Pfizer Inc. (NYSE: PFE) today announced that Frank D’Amelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply at Pfizer after a nearly 15 year distinguished career with the Company.
-
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
11/16/2021
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
-
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States
11/9/2021
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States
-
PFIZER REPORTS THIRD-QUARTER 2021 RESULTS
11/2/2021
Pfizer Inc. reported financial results for third-quarter 2021 and raised 2021 guidance(4) for revenues and Adjusted diluted EPS(3)
-
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
9/24/2021
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for somatrogon
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call with Analysts
9/23/2021
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 2, 2021.
-
Pfizer Declares Fourth-Quarter 2021 Dividend
9/23/2021
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent fourth-quarter 2021 dividend on the company’s common stock, payable December 6, 2021, to holders of the Common Stock of record at the close of business on November 5, 2021.